Background: Lung adenosquamous carcinomas (ASC) are morphologically mixed tumors that contain the two cell components adenocarcinomas (AC) and squamous cell carcinomas (SCC). However, to date, the genomic profile, TMB status, evolutionary relationship, and immune microenvironment of the two components still remain unclear. Method: Adenocarcinomas component (ACC) and squamous cell carcinomas component (SCCC) in ASC (n¼30) were validated by immunohistochemistry and obtained separately by means of laser capture microdissection. Gene panel and T cell receptor (TCR) repertoire sequencing were performed in both components. Normal tissues adjacent to the cancer were used as controls. The two components were compared from the dimension of somatic mutations, TMB, evolution, and the TCR clones. 626 AC tumors and 83 SCC tumors were also included for comparison with ASC. Results: Comparison of frequency of recurrently altered genes in lung SCCC, ACC, AC, and SCC were performed. EGFR (Fisher Exact test, p¼0.0476, OR 2.6) and MAP3K1 (p¼0.0020, OR 10.2) were enriched but no KRAS were found in ACC compared to AC. Compared with SCC, EGFR (p<0.0001, OR 14.3) is enriched in SCCC, while TP53 (p¼0.0129, OR 0.3) with lower mutation frequency. Different mutational spectra suggest that ACC is different from AC, and SCCC is different from SCC. Despite the heterogeneity, there were shared mutations in lung SCCC and ACC. 79% of ACC and 75% of SCCC samples harbored EGFR mutations. 46% of ACC and 64% of SCCC samples harbored TP53 mutations. In the evolutionary tree analysis, EGFR (in 75% of patients) and TP53 (43%) are the most frequent trunk genes. Above 90% (27/28) of patients had trunk genes, indicating that SCCC and ACC in ASC come from the same origin. In ACC, SCCC, AC, and SCC, 14%, 29%, 23%, and 48% of samples were identified as TMB-H respectively. The TMB index of SCCC was higher than that of ACC (Wilcoxon matched pairs test, p¼0.0065). The ACC TMB was equivalent to AC (Mann-Whitney test, p¼0.9352). The SCCC TMB is marginally lower than SCC (Mann-Whitney test, p¼0.0553). Significant difference is showed in the diversity of TCRs between ACC and SCCC (Wilcoxon matched pairs test, p¼0.0383). Although the difference is not significant, 65% (14/20) of SCC samples have a higher clonality index than ACC. Conclusion: Our study promote a better knowledge about ACC and SCCC from ASC, supporting the hypothesis that ACC and SCCC in ASC come from the same origin. However, two components also exhibit diverse genomic profile, TMB status, and TCR repertoire. Keywords: lung adenosquamous carcinomas, Genomic profile, T cell receptor repertoire 
Background: Uniportal segmentectomy is a therapeutic option for small lung nodule, but the debate over uniportal segmentectomy still remains. The aim of this study is to evaluate of efficacy and safety of uniportal segmentectomy in the treatment of small lung nodule. Method: A total of 85 patients who underwent uniportal segmentectomy or subsegmentectomy between January 2017 and September 2018 in Liaoning Cancer Hospital. The clinical data of these patients were retrospectively analyzed, including operation time, number of lymph nodes dissected and postoperative mortality, postoperative complications, postoperative intubation time, and postoperative hospital stay. Results: The surgery procedure was anatomical pulmonary segmentectomy or subsegmentectomy. Uniportal segmentectomy was in 81 cases, and subsegmentectomy was in 4 cases. The median operation time was 243 minutes (range, 60-405 minutes), median number of lymph nodes dissected was 14 (range, 0-31), median postoperative intubation time was 5 days (range, 1-9 days), median postoperative hospital stay was 8 days (range, 3-19 days). The postoperative complications were pneumonia 1 case (1.2%), fever 9 cases (10.6%), hemoptysis 1 case (1.2%), air leak 1 case (1.2%), atrial fibrillation 1 case (1.2%), and subcutaneous hydrops 2 cases (2.4%). There was no severe postoperative complications, including death, bleeding, reoperation, and bronchopleural fistula. Background: Brain metastasis (BM) is associated with poor prognosis, recurrence, and death in patients with non-small cell lung cancer (NSCLC). Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been reported to be involved in the progression, metastasis and recurrence of malignancies. However, the potential role of LPCAT1 in NSCLC remains poorly understood. This study was aimed to identify genes involved in NSCLC brain metastasis, and look into the role of LPCAT1 in NSCLC progression. Method: We used integrative genomic analysis to identify genes involved in lung adenocarcinomas. LPCAT1 expression was evaluated in tumor tissue from NSCLC patients and NSCLC cell lines. The role of LPCAT1 was subsequently investigated both in vitro and in vivo by short hairpin RNA (shRNA)-mediated knockdown in NSCLC cell lines. The mechanism underlying the involvement of LPCAT1 in NSCLC progression was explored by using activator of PI3K/AKT pathway. RNA sequencing was performed to confirm the involvement and pathway of LPCAT1 in NSCLC brain metastasis. Results: LPCAT1 was upregulated in NSCLC tissues and cell lines. shRNA-mediated depletion of LPCAT1 abrogated cell proliferation, migration and invasion in vitro, and arrested tumor growth and brain metastases in vivo as well. Moreover, LPCAT1 regulated NSCLC progression, at least in part, through PI3K/AKT signal pathway by targeting MYC transcription. RNA-sequencing revealed that LPCAT1 was higher in tissues of NSCLC patients with BM than those without BM. Finally, elevated LPCAT1 expression in patients with lung adenocarcinomas was associated with a poor clinical outcome. Conclusion: This study showed that LPCAT1 works as a regulator of cell metastasis and may serve as a novel therapeutic target for BM in NSCLC. Keywords: LPCAT1, NSCLC brain metastasis, PI3K/AKT/ MYC signaling
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